KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesLong-Term Debt IssuancesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetReceivables - OtherShares IssuedShares OutstandingShares Outstanding
Ratios

ClearPoint Neuro (CLPT) EBIAT (2016 - 2026)

ClearPoint Neuro's EBIAT history spans 13 years, with the latest figure at -$7.8 million for Q4 2025.

  • On a quarterly basis, EBIAT fell 44.56% to -$7.8 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$25.5 million, a 35.03% decrease, with the full-year FY2025 number at -$25.5 million, down 35.03% from a year prior.
  • EBIAT hit -$7.8 million in Q4 2025 for ClearPoint Neuro, down from -$5.9 million in the prior quarter.
  • Over the last five years, EBIAT for CLPT hit a ceiling of -$2.5 million in Q1 2021 and a floor of -$7.8 million in Q4 2025.
  • Historically, EBIAT has averaged -$4.9 million across 5 years, with a median of -$4.5 million in 2023.
  • Biggest five-year swings in EBIAT: plummeted 168.19% in 2021 and later skyrocketed 37.49% in 2024.
  • Tracing CLPT's EBIAT over 5 years: stood at -$4.1 million in 2021, then decreased by 5.69% to -$4.4 million in 2022, then fell by 5.34% to -$4.6 million in 2023, then decreased by 16.61% to -$5.4 million in 2024, then tumbled by 44.56% to -$7.8 million in 2025.
  • Business Quant data shows EBIAT for CLPT at -$7.8 million in Q4 2025, -$5.9 million in Q3 2025, and -$5.8 million in Q2 2025.